卵巢癌FZOCUS-1研究登顶全球肿瘤学顶级期刊

Core Viewpoint - The FZOCUS-1 study has been published in the prestigious journal "CA: A Cancer Journal for Clinicians," marking a significant milestone for Chinese clinical oncology research and demonstrating China's leadership in gynecological oncology research on a global scale [1][6]. Group 1: Study Overview - The FZOCUS-1 study is a randomized, double-blind, placebo-controlled Phase III clinical trial conducted over six years across 54 centers in China, involving 674 patients [4]. - The study aims to evaluate the efficacy and safety of the first domestically developed PARP inhibitor, Fluorouracil, either alone or in combination with the anti-angiogenic drug Apatinib, for first-line maintenance treatment of advanced ovarian cancer [4]. Group 2: Clinical Context - Ovarian cancer, known as the "king of gynecological cancers," is characterized by late-stage diagnosis, high recurrence rates, and poor long-term prognosis, with less than 30% five-year survival rate for advanced cases [3]. - Traditional treatment methods have limited effectiveness, with up to 70% of patients facing recurrence within two years, leading to a cycle of treatment and relapse [3]. Group 3: Implications and Accessibility - The successful publication of the FZOCUS-1 study provides critical evidence for clinical practice in advanced ovarian cancer, contributing both breakthrough advancements and precision treatment options [4][6]. - The PARP inhibitor Fluorouracil has been included in the medical insurance directory, significantly improving drug accessibility for Chinese ovarian cancer patients [6].